Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
Saved in:
| Title: | Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. |
|---|---|
| Authors: | McGrail, D.J.1,2 (AUTHOR) mcgraid@ccf.org, Pilié, P.G.3 (AUTHOR), Rashid, N.U.4,5 (AUTHOR), Voorwerk, L.6 (AUTHOR), Slagter, M.7,8,9 (AUTHOR), Kok, M.6,10 (AUTHOR), Jonasch, E.3 (AUTHOR), Khasraw, M.11 (AUTHOR), Heimberger, A.B.12 (AUTHOR), Ueno, N.T.13 (AUTHOR), Ferrarotto, R.14 (AUTHOR), Chang, J.T.15,16 (AUTHOR), Lin, S.-Y.17 (AUTHOR) |
| Source: | Annals of Oncology. Nov2022, Vol. 33 Issue 11, p1204-1206. 3p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.009 |
